Adial Pharmaceuticals Announces Planned Appointment of Celia Economides as Chief Financial Officer
Adial Pharmaceuticals announced that Celia Economides, currently EVP of Finance, is expected to be appointed CFO promptly after the reconvened 2026 annual meeting, succeeding Vinay Shah, contingent on stockholder approval of pending proposals. Economides brings 20+ years of biotech finance experience and has helped raise more than $1 billion across prior roles at Aurinia, Kezar, Gritstone and CellCentric. The CFO appointment accompanies a planned transition: if stockholders approve the Series A preferred conversion and Nasdaq approves the initial listing application, Adial will rename to Azora Therapeutics and trade under the symbol AZR.
Key figures
- New name
- Azora Therapeutics, Inc.
- New ticker
- AZR
- Phase 1 planned
- first half of 2027
- Capital raised career
- more than $1 billion
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.